EU secures additional 100 million doses of Pfizer-BioNTech vaccine for 2021 delivery
Extra supply will bring total number of doses scheduled to be shipped to EU this year to 600 million
The European Union has secured another 100 million doses of the Pfizer-BioNTech COVID-19 vaccine, Comirnaty, for delivery in 2021 after activating a clause in an existing supply contract, the two companies said Monday.
The European Commission’s decision to exercise an option in the advance purchase agreement signed in February brings the total number of doses of the vaccine to be delivered to the 27 EU member states this year to 600 million.
“We now intend to deliver a total of 600 million doses to the EU this year, which covers two thirds of the EU population and represents the largest cumulative supply agreement for Comirnaty that we have agreed to date globally,” said Sean Marett, Chief Business and Chief Commercial Officer of BioNTech.
Pfizer CEO, Albert Bourla, said to date the company had met all of it supply commitments to the EC and planned to deliver 250 million doses to the EU in Q2, “a four-fold increase on Q1’s agreed quantity.”
Back in January, shipments of the vaccine to the bloc were affected by what Pfizer and BioNTech said were changes to the manufacturing processes designed to increase production capacity, but at the time the companies insisted the bottlenecks were only temporary.
The EU has been looking to offset the impact of delays to Johnson & Johnson’s single-shot vaccine, after US regulators review links to rare cases of blood clotting, as well as several member states’ decisions to restrict usage of AstraZeneca’s vaccine.
Last week, the Danish Health Authority removed the AstraZeneca shot entirely from its inoculation programme, saying that based on scientific findings, it had determined there was a real risk of severe side effects with using it.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance